A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care

Cardiologist Anees A. Daud, MD, highlights how a cardiologist may followup with patients receiving androgen deprivation therapy and how multidisciplinary care plays a role in this setting.

EP: 1.Cardiovascular Disease Risk in Men with Prostate Cancer

EP: 2.Examining the Data From Key Clinical Trials, and Practical Strategies

EP: 3.Strategies for Mitigating Cardiovascular Risk

EP: 4.Summary and Case Study

EP: 5.A Medical Oncologist Reflects on a Typical Prostate Cancer Patient

EP: 6.A Urologist Reflects on a Typical Prostate Cancer Patient

EP: 7.A Cardiologist Reflects on a Typical Prostate Cancer Patient

EP: 8.Practice-Related And Provider-Patient Communication Strategies For Prostate Cancer Care

EP: 9.A Cardiologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 10.A Medical Oncologist’s Perspective on Cardiovascular Risk Assessment in Prostate Cancer

EP: 11.Typical Examinations And Tests For Cardiovascular Risk Assessment in a Cardiology Practice

EP: 12.Typical Examinations And Tests For Cardiovascular Risk Assessment in an Oncology Practice

EP: 13.A Cardiologist’s Recommended Interventions For Cardiovascular Risk Mitigation

EP: 14.A Medical Oncologist’s Recommended Interventions For CV Risk Mitigation

EP: 15.Strategies For Communicating Cardiovascular Risk to Patients Starting on ADT

EP: 16.Considerations For ADT Selection And Patient Education on Treatment-Related AEs

EP: 17.A Urologist’s Approach to Followup For Patients on ADT And Practice Communication Strategies

Now Viewing

EP: 18.A Cardiologist’s Approach to Followup For Patients on ADT and Strategies in Multidisciplinary Care

EP: 19.A Urologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

EP: 20.A Cardiologist Reacts to AbbVie’s Educational Video: Key Takeaways And Clinical Impact

January 2023 AbbVie Inc. Company Confidential

Related Videos

Related Content

Advertisement

November 21st 2024

Targeted microwave ablation shows precision, safety in localized prostate cancer

Hannah Clarke

In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

November 20th 2024

Study indicates overtreatment of men with prostate cancer and limited life expectancy

Hannah Clarke

“Prostate cancer patients with life expectancies of less than 5 or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, despite guidelines recommending against treatment," says Timothy J. Daskivich, MD.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

November 8th 2024

Study characterizes long-term impact of prostate cancer treatment

Hannah Clarke

“Our study is distinguished by long follow-up, out to 12 years, looking at a broad spectrum of key complications," says Joseph M. Unger, PhD.

November 7th 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated

Hannah Clarke

The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.

Related Content

Advertisement

November 21st 2024

Targeted microwave ablation shows precision, safety in localized prostate cancer

Hannah Clarke

In the recent news release, Koelis reported that the final patient was enrolled in the VIOLETTE study in September 2024.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

November 20th 2024

Study indicates overtreatment of men with prostate cancer and limited life expectancy

Hannah Clarke

“Prostate cancer patients with life expectancies of less than 5 or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, despite guidelines recommending against treatment," says Timothy J. Daskivich, MD.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

November 8th 2024

Study characterizes long-term impact of prostate cancer treatment

Hannah Clarke

“Our study is distinguished by long follow-up, out to 12 years, looking at a broad spectrum of key complications," says Joseph M. Unger, PhD.

November 7th 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated

Hannah Clarke

The decision was based on an interim readout from the trial, which showed that ONCT-534 did not lead to any clinically meaningful improvement of disease.